Effects of dexfenfluramine or 5,7-dihydroxytryptamine on tryptophan hydroxylase and serotonin transporter mRNAS in rat dorsal raphe

Molecular Brain Research

Volumn 41, Issue 1-2, 1996, Pages 121-127

  Semple Rowland, Susan L ^a   Mahatme, Arvind ^a   Rowland, Neil E ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE   (United States)

Author keywords

5,7 dihydroxytryptamine; Dexfenfluramine; Dorsal raphe nucleus; Polymerase chain reaction; Serotonin transporter mRNA; Tryptophan hydroxylase mRNA

Indexed keywords

5,7 DIHYDROXYTRYPTAMINE; CARRIER PROTEIN; DEXFENFLURAMINE; MESSENGER RNA; PAROXETINE; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; FOREBRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

EID: 0030570981     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-328X(96)00076-9     Document Type: Article

References (26)

1. Appel N.M., Contrera J.F., De Souza E.B. Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: evidence from immunocytochemical studies. J. Pharmacol. Exp. Ther. 249:1989;928-943.
2. Appel N.M., Mitchell W.M., Contrera J.F., De Souza E.B. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse. 6:1990;33-44.
3. 3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242:1987;911-916.
4. Baumgarten, H.G., Lachenmayer, L. and Bjorklund, A., Chemical lesioning of indoleamine pathways. In: R.D. Myers (Ed.), Methods in Psychobiology, Vol. III, Academic Press, New York, 1977, pp. 47-98.
5. Bendotti C., Baldessari S., Ehret M., Tarizzo G., Samanin R. Effect of D-fenfluramine and 5,7-dihydroxytryptamine on the levels of tryptophan-5-hydroxylase and its mRNA in rat brain. Mol. Brain Res. 19:1993;257-261.
6. Bendotti C., Servadio A., Forloni G., Angeretti N., Samanin R. Increased tryptophan hydroxylase mRNA in raphe serotonergic neurons spared by 5,7-dihydroxytryptamine. Mol. Brain Res. 8:1990;343-348.
7. Blakely R.D., Berson H.E., Fremeau R.T., Caron M.C., Peek M.M., Prince H.K., Bradley C.C. Cloning and expression of functional serotonin transporter from rat brain. Nature. 354:1991;66-70.
8. Brzezinski A.A., Wurtman J.J., Wurtman R.J., Gleason R., Greenfield J., Nader T. D-fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet. Gynecol. 76:1990;296-301.
9. Caccia S., Anelli M., Ferrarese A., Fracasso C., Garattini S. Single- and multiple-dose kinetics of D-fenfluramine in rats given anorectic and toxic doses. Xenobiotica. 22:1992;217-226.
10. Caccia S., Sarati S., Anelli M., Garattini S. Effect of escalating doses of D-fenfluramine on the content of indoles in brain. Neuropharmacology. 31:1992;875-879.
11. Darmon M.C., Guibert B., Leviel V., Ehret M., Maitre M., Mallet J. Sequence of two mRNAs encoding active tryptophan hydroxylase. J. Neurochem. 51:1988;312-316.
12. Fattaccini C.M., Gozlan H., Hamon M. Differential effects of D-fenfluramine and p-chloroamphetamine on H75/12-induced depletion of 5-hydroxytryptamine and dopamine in the rat brain. Neuropharmacology. 30:1991;15-23.
13. Gardier A.M., Kaakkola S., Erfurth A., Wurtman R.J. Effects of methiothepin on changes in brain serotonin release induced by repeated administration of high doses of anorectic serotoninergic drugs. Brain Res. 588:1992;67-74.
14. Guy-Grand B. INDEX (International Dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s. Intl. J. Obesity. 16((Suppl. 3)):1992;S5-S14.
15. 3H]paroxetine binding to rat cortical membrane. Eur. J. Pharmacol. 118:1985;107-114.
16. Kalia M. Reversible, short-lasting, and dose-dependent effect of (+)-fenfluramine on neocortical serotonergic axons. Brain Res. 548:1991;111-125.
17. Lehmann J., DeSouza E.B., Culp S., Zaczek R. Regional distribution to recovery of 5-HT levels after administration of `atrophins' MDMA and D,L-fenfluramine: stereospecificity and comparison with 5,7-dihydroxytryptamine. Ann. NY Acad. Sci. 648:1992;291-296.
18. Lesch K.P., Aulakh C.S., Wolozin B.L., Tolliver T.J., Hill J.L., Murphy D.L. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol. Brain Res. 17:1993;31-35.
19. McTavish D., Heel R.C. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 43:1992;713-733.
20. O'Hearn E., Battaglia G., DeSouza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedimethoxyamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8:1988;2788-2803.
21. Paxinos G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, 1986.
22. Rattray M., Wotherspoon G., Savery D., Baldessari S., Marden C., Priestley J.V., Bendotti C. Chronic D-fenfluramine decreases serotonin transporter messenger RNA expression in dorsal raphe nucleus. Eur. J. Pharmacol. 268:1994;439-442.
23. Rowland N.E., Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog. Neurobiol. 27:1986;13-62.
24. Rowland N.E., Kalehua A.N., Li B.-H., Semple-Rowland S.L., Streit W.J. Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain Res. 624:1993;35-43.
25. Sambrook, J., Fritsch, E.F. and Manatis, T., Molecular Cloning: a Laboratory Manual, 2nd edn., Cold Spring Harbor Press, 1989, pp. 7.19-7.22.
26. Semple-Rowland S.L., Mahatme A., Popovich P.G., Green D.A., Hassler G., Stokes B.T., Streit W.J. Analysis of TGF-B1 gene expression in contused rat spinal cord using quantitative RT-PCR. J. Neurotrauma. 12:1995;1003-1014.